In this episode of his “Conversations With Perry and Friends” podcast, Perry Cohen, Pharm.D., a member of the Managed ...
The Chosun Ilbo on MSN
Government, Pharma Clash Over Generic Drug Prices
Government, Pharma Clash Over Generic Drug Prices Government cuts generic prices for new drugs; industry fears R&D impact ...
Clinical Trials Arena on MSN
AI can reduce R&D costs to alleviate looming patent cliff pressures
Speaking at CDMI Europe 2025, GlobalData pharma analyst George El-Helou says the use of AI in R&D could help mitigate patent ...
On 1 December, the fortunes of the UK pharma sector changed radically, with the UK Government becoming the first in the world ...
GoodRx reports seven ways to save on prescription costs with Medicare Part D, including state resources, generic medications, ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...
DCOIWA asks DCGI to amend recruitment rules to include Pharm.D graduates for the post of drug inspectors: ...
Medicus Pharma Ltd. (Nasdaq:MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical ...
Citi Annual Global Healthcare Conference 2025 December 2, 2025 3:15 PM ESTCompany ParticipantsTerrance Coyne - Executive VP ...
Discover how new U.S. Medicare drug price cuts impact major pharma stocks like Novo Nordisk and why sector resilience ...
Accreditation Commission for Health Care accredits McLeod Health’s pharmacy. It serves patients in Florence County with ...
Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback